Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Hepatology. 2021 May 24;74(3):1411–1428. doi: 10.1002/hep.31817

Figure 8: Working model for the effect of SULF2 monoclonal antibody 5D5 on PDGFRβ-YAP signaling in CCA.

Figure 8:

SULF2 increases the activity of the PDGFRβ-YAP pathway to promote tumor growth and chemotherapy resistance. Targeting SULF2 by monoclonal antibody 5D5 showed inhibition of the PDGFRβ-YAP pathway and CCA growth in a mouse model.